Skip to content
value.today

CV Sciences, Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value and what the price assumes

$M

Average of FY2023–FY2025 (cash from operations less capital spending), from the statements below.

%

Starts at revenue growth over the last three years, -5.2% a year (statements).

%

US Treasury 10-year yield on Nov 13, 2026: 5.15% (US Treasury).

%

Your assumption: the extra yearly return you want for holding shares rather than Treasuries. 5% is a round starting figure, not data.

%

Your assumption: long-run growth, usually near inflation. It must stay below the discount rate.

$M

Debt less cash at the end of FY2025 (statements); negative means more cash than debt.

What today's price assumes

The price's implied growth cannot be worked out with these figures (it needs a positive cash flow, a market value and a discount rate above long-run growth).

Cash-flow value of the shares
$1 M
Value of the whole business
$2 M
before net debt
Value from after year 10
38%
of the business value

Against the market value, for other rates

Cash-flow value of the shares as a percentage above or below today's market value; your inputs in the middle.

Sensitivity of the cash-flow value to the discount rate and the growth rate
Discount rate ↓ / growth →-10.23%-7.73%-5.23%-2.73%-0.23%
8.15%—————
9.15%—————
10.15%—————
11.15%—————
12.15%—————

On one scale

Bars: from the 25th to the 75th percentile multiple of the peers, the line at the median; dot: the cash-flow value with your inputs.

Price to salesPrice to sales of Pharmaceutical: $21 M to $91 M, median $48 MPrice to bookPrice to book of Pharmaceutical: $3 M to $12 M, median $6 MCash-flow value$0 M$24 M$49 M$73 M$98 M

Your own DCF model

A full discounted-cash-flow model of CV Sciences, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Pharmaceutical

Multiples of its companies with a market value at most 60 days old, times CV Sciences, Inc.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)CV Sciences, Inc.Applied toValue (25th to 75th)Companies
Price to sales1.5× / 3.5× / 6.6×—revenue $14 M$21 M to $91 M69
Price to book2.1× / 4.0× / 8.3×—book equity $1 M$3 M to $12 M63

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025$14 M$-1 M$-0 M$0 M$-1 M$1 MSEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024$16 M$-2 M$-1 M$0 M$-1 M$-0 MSEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023$16 M$3 M$2 M$0 M$2 M—SEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$16 M$-8 M$-2 M$0 M$-2 M—SEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$20 M$-16 M$-7 M$0 M$-8 M$-1 MSEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$24 M$-22 M$-7 M$1 M$-8 M$-3 MSEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value not on file.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.